|Bid||11.77 x 100|
|Ask||15.00 x 300|
|Day's range||14.28 - 14.69|
|52-week range||10.30 - 14.87|
|PE ratio (TTM)||17.00|
|Earnings date||7 Feb 2018 - 12 Feb 2018|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||12.40|
Innoviva, Inc. today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease .
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna ...
Innoviva, Inc. today announced that management will present at the following healthcare-focused investment banking conferences in November 2017:
The Brisbane, California-based company said it had profit of 21 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Innoviva, Inc. today reported financial results for the third quarter of 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® from Glaxo Group Limited during the third quarter of 2017 were $51.9 million, up 42% from $36.5 million in the third quarter of 2016.
Innoviva, Inc. announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017.
The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of Trelegy ...
The Brisbane, California-based company said it had profit of 30 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
The Brisbane, California-based company said it had profit of 15 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
The Brisbane, California-based company said it had profit of 22 cents per share. Earnings, adjusted for amortization costs and stock option expense, were 26 cents per share. The results topped Wall Street ...